Keryx Biopharmaceuticals shares were up 21% in pre-market trade after the company announced its kidney disease medication met phase 3 endpoints early Tuesday. The ferric citrate medication is intended to treat iron deficiency anemia in adults with chronic kidney disease, which about 1.6 million Americans are affected by, the company said. The phase 3 results of the 24-week, 234-patient trial were statistically significant and met primary and pre-specified secondary endpoints, the company said.
Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.
From:: Stock Market News